| Date | Title | Description |
| 05.03.2024 | Business wind down and take off for listed Swiss startups |
Since its inception in 2012, ObsEva SA (SIX: OBSN) has focused on the development of novel therapies for women's health and pregnancy, with a program focused on improving in vitro fertilization success rates. Due to low cash reserves, the ... |
| 09.12.2022 | ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – December 9, 2022 – ObsEva SA OBSVOBSN)), a biopharmaceutical company developing and commercializing novel therapies for women's health, announced tod... |
| 25.11.2022 | Obseva sells rights to its preterm labor treatment for up to $115 million | |
| 22.11.2022 | ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million | - |
| 22.11.2022 | ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million | Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness pos... |
| 13.09.2022 | ObsEva Announces Progress on Restructuring Initiatives | $7.6 million annual savings expected via reduction-in-force currently underway $6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd., including $1.7 million of accounts payab... |
| 24.08.2022 | Swiss biotechs in dispute with regulators | |
| 20.06.2022 | Obseva receives its first European Marketing Authorization | |
| 31.01.2022 | ObsEva Announces Corporate Updates | GENEVA, Switzerland - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, announced that its board of directors approved on January 28, 2022 an increase of its ... |
| 29.01.2022 | ObsEva Announces Corporate Updates | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – January 28, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health... |
| 29.01.2022 | ObsEva : Announces Corporate Updates - Form 6-K | ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland - January 28, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing... |
| 06.01.2022 | ObsEva : Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain | January 6, 2022
-Once daily linzagolix 200mg with ABTmet both co-primary efficacy objectives, demonstrating reductions in dysmenorrheaand non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically ... |
| 06.01.2022 | ObsEva announces positive results from Phase 3 trials | |
| 30.10.2021 | ObsEva Announces Management Change - Form 6-K | ObsEva Announces Management Change
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland - October 29, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializin... |
| 30.10.2021 | Press Release : ObsEva Announces Management Change | Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland -- October 29, 2021 -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve wome... |
| 19.10.2021 | ObsEva : Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo | –Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis–
GENEVA, Switzerland October 19, 2021 – ObsEva SA (NASDAQ:... |
| 19.10.2021 | Press Release : ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo | --Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis--
GENEVA, Switzerland October 19, 2021 -- ObsEva SA (NASD... |
| 14.10.2021 | ObsEva : Announces Relationship with Syneos Health to Commercialize Linzagolix - Form 6-K/A | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-
-Financing agreement with JGB Ma... |
| 13.10.2021 | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-
-Financing agreement with JGB Ma... |
| 13.10.2021 | ObsEva : Announces Relationship with Syneos Health to Commercialize Linzagolix - Form 6-K | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-
-Financing agreement with JGB Ma... |
| 13.10.2021 | Press Release : ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix | ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-
-Financing agreement with JGB Ma... |
| 15.09.2021 | ObsEva : Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids | -If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids-
-NDA submission includes positive data from Phase 3 PRIMROSE trials up to 52 wee... |
| 15.09.2021 | Press Release : ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids | -If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids-
-NDA submission includes positive data from Phase 3 PRIMROSE trials up to 52 wee... |
| 11.08.2021 | Timber Pharmaceuticals : 7 Hottest Penny Stocks to Pick Up Now | 7 Hottest Penny Stocks to Pick Up Now
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
I believe there's not a single person out there who believes we're not in an extended bull-market. With economic growth and artificiall... |
| 05.08.2021 | Press Release : ObsEva Announces Second Quarter 2021 Financial Results and Business Update | -Linzagolix (Yselty(R)) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-
-Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study
expected i... |
| 05.08.2021 | ObsEva receives USD 500 million in upfront and milestone payments | Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront... |
| 04.08.2021 | Press Release : ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF | - A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-
-A Mechanism of Action Trial Assessing the Effect o... |
| 04.08.2021 | ObsEva : Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF | - A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-
-A Mechanism of Action Trial Assessing the Effect o... |
| 02.06.2021 | OBSEVA SA
Press Release : ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 | - Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA -- June 2, 2021 -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a... |
| 02.06.2021 | OBSEVA SA
Press Release: ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 | - Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA -- June 2, 2021 -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a... |
| 26.05.2021 | OBSEVA SA
ObsEva : Press Release 25 May 2021 1 | ObsEva Announces Proposed Changes to the Composition of its
Board of Directors
Geneva, Switzerland and Boston, MA - May 25, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therap... |
| 20.05.2021 | OBSEVA SA
Press Release : ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty(R) (linzagolix) for the Treatment of Uterine Fibroids | -PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue to support the differentiated profile of Yse... |
| 20.05.2021 | OBSEVA SA
ObsEva : Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids (Form 6-K) | ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
Yselty® (linzagolix) for the Treatment of Uterine Fibroids
-PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment
effects and evidence of bone... |
| 06.05.2021 | OBSEVA SA
Press Release : ObsEva Announces First Quarter 2021 Financial Results and Business Update | -Yselty(R) for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty(R) for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -... |
| 06.05.2021 | Press Release: ObsEva Announces First Quarter 2021 Financial Results and Business Update | -Yselty(R) for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty(R) for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -... |
| 04.05.2021 | OBSEVA SA
Press Release : ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain | - EDELWEISS 3 trial of Yselty(R) expected to report topline data as planned in Q4:21- GENEVA, Switzerland and BOSTON, MA -- May 4, 2021 -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing nove... |
| 30.04.2021 | OBSEVA SA
Press Release : ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021 | GENEVA, Switzerland and BOSTON, MA -- April 30, 2021 -- ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the presentation... |
| 27.04.2021 | OBSEVA SA
Press Release : ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants | -Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 - GENEVA, Switzerland and BOSTON, MA -- April 27, 2021 -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN... |
| 10.11.2020 | Startups under new leadership | CodeCheck appoints CEO and CFO
With its app for evaluating products, CodeCheck has continued to empower consumers to buy the healthiest and most environmentally friendly products. The company seeks to internationalise its app with the suppo... |
| 10.11.2020 | Startups under new leadership | |
| 05.11.2020 | ObsEva Announces Third Quarter 2020 Financial Results and Business Update | Positive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual Congress
Linzagolix regulatory submissions planned for Q4... |
| 06.08.2020 | OBSEVA SA
ObsEva : Q2 Half Year Report 2020 | Half-Year Report 2020
Interim Condensed Consolidated IFRS
Financial Statements for the three-month and six-month periods ended June 30, 2020
(unaudited)
ObsEva SA
Interim Condensed Consolidated IFRS Financial Statements for the three-month ... |
| 07.11.2019 | ObsEva shares crater after PhIII fail; Allena Pharma unveils positive late-stage data | → Swiss biotech ObsEva SA — focused on treatments to improve women’s reproductive health — shared some dismal news today when it announced that its Phase III clinical trial of nolasiban in women undergoing embryo trans... |
| 08.08.2019 | ObsEva secures $75 million non-dilutive financing | |
| 07.08.2019 | ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC | - |
| 19.07.2019 | Medicxi closes a €400M Fund to back biopharma entrepreneurs | |
| 13.07.2018 | ObsEva with a positive start at Swiss Exchange | |
| 18.06.2018 | Seven biotech IPOs ready to roll; Celltrion's Herceptin biosim gets second review at FDA | → Renaissance Capital is tracking 7 new biotech IPOs this week. The lineup includes Magenta, Avrobio and Autolus, all high-profile ventures that will be testing the market again.
→ Forty Seven set terms on its IPO, looking... |
| 01.03.2018 | ObsEva Reports Positive Phase 3 Results | |
| 10.10.2017 | ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors | Geneva, Switzerland and Boston, MA – 10 October, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a wom... |
| 02.03.2017 | Eclosion: Incubator for market stars in Geneva | |
| 05.02.2017 | The rise of femtech: women, technology, and Trump | The market is flooded with products tailored to the needs of men: viagra, penis enlargement pills, fitness apps, and more. But a new sector dedicated to women is emerging. Femtech, or female technology, is tickling the curiosity of hungry v... |
| 05.02.2017 | The rise of femtech: women, technology, and Trump | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more.
The market is flooded with products tailored to the needs of men: viagra, penis enlargement pills, fitness apps, and more. But a new se... |
| 18.01.2017 | ObsEva Expands Leadership Team as it prepares for IPO | |
| 18.01.2017 | Women’s health biotech ObsEva sets terms for $87M IPO | ObsEva has set the terms for an IPO that could net it in the region of $87 million (€81 million). The haul, around half of which will come from insiders, will enable ObsEva to move a treatment for heavy menstrual bleeding associated with ut... |
| 31.10.2016 | ObsEva announces IPO and Phase 3 clinical trials | |
| 04.08.2016 | ObsEva: Fifth compound in a clinical program | |
| 25.02.2016 | How to raise CHF100 million | |
| 24.11.2015 | ObsEva Closes CHF 60 Million in Series B Financing | |
| 23.11.2015 | ObsEva Closes US$60M Series B Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, closed a CHF60 (US$60m) Series B equity financing.
Backers i... |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| 11.09.2015 | ObsEva presents encouraging results of the pharmacology studies | |
| 03.03.2015 | ObsEva Reports Positive Phase 1 Results for Its Lead Compound Treating Preterm Labour | |
| 28.11.2014 | ObsEva Announces Initiation of a Pivotal Phase 2 Study | |
| 29.01.2014 | New Chairperson of the Board at ObsEva | |
| 29.08.2013 | ObsEva grabs $34.5M to launch out of Merck Serono rubble | Another biotech company is being assembled out of the wreckage left behind by Merck KGaA's restructuring in Europe. Sofinnova Ventures and Novo A/S led a $34.5 million Series A round for ObsEva, a Geneva-based biotech that is snatching up M... |
| 29.08.2013 | ObsEva SA announces CHF 32 Million funding | |
| 29.08.2013 | ObsEva Raises EURO 25.6M in Series A |
GENEVA, SWITZERLAND, ObsEva today announced the closing of a CHF 32 million Series-A financing round (EUR 25.6 million).
>> Click here for more funding data on ObsEva
>> To export ObsEva funding data to PDF and Excel, click ... |
| 29.08.2013 | ObsEva Closes CHF32M Series A Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine, closed a CHF32m (approximately €25.6m) Series A financing round.
The round was led by Sofinnov... |
| - | Stocks making the biggest moves midday: Abercrombie & Fitch, Disney, Best Buy, Zoom and more | Check out the companies making headlines in midday trading.
Abercrombie & Fitch – Shares of the retail stock jumped 21.4% after the apparel retailer beat Wall Street's revenue forecasts for the third quarter and posted unexpected quarte... |